Oral Surgery, Oral Medicine, Oral Pathology
Effects of pilocarpine on salivary flow in patients with Sjo¨gren's syndrome
Reference (15)
Biological activities in human labial and palatine secretions
Arch Oral Biol
(1975)- et al.
Labial salivary gland biopsy in Sjo¨gren's disease
J Clin Pathol
(1968) - et al.
The oral component of Sjo¨gren's syndrome
J Oral Surg
(1976) Sjo¨gren's syndrome: newer aspects of research, diagnosis, and therapy
Ann Intern Med
(1971)Sjo¨gren's syndrome: current issues—part I
Ann Intern Med
(1980)Detection and management of the dental patient with Sjo¨gren's syndrome
Comp Cont Ed Dent
(1986)
Cited by (59)
Engineering the mode of morphogenetic signal presentation to promote branching from salivary gland spheroids in 3D hydrogels
2020, Acta BiomaterialiaCitation Excerpt :On the other hand, late xerostomia is caused by gland fibrosis, is permanent and can occur up to one year after the radiation treatment [6,7]. Another cause of xerostomia is Sjögren Syndrome (SS), an autoimmune disease where the host immune cells target exocrine glands leading to hyposalivation [6,8,9]. Together, radiation therapy and SS cause loss in saliva quality and quantity that significantly decreases the quality of life of millions of patients.
Exploratory study on reduction of the incidence of hyperhidrosis by oral pilocarpine
2014, Journal of Oral and Maxillofacial Surgery, Medicine, and PathologyCitation Excerpt :Xerostomia associated with Sjögren's syndrome is treated effectively with cevimeline hydrochloride hydrate and oral pilocarpine [1–6].
Management of xerostomia and other complications of Sjögren's syndrome
2014, Oral and Maxillofacial Surgery Clinics of North AmericaCitation Excerpt :Briefly, studies were assessed for risk of bias, inconsistency of the direction of results across studies, precision of effect estimates, use of surrogate outcomes (indirectness), and publication bias (available at: http://www.gradeworkinggroup.org/index.htm) (Table 2). Extensive literature has been published focusing on the effect of therapeutic interventions for the management of xerostomia and reduced salivary flow in SS: 43 studies included assessment of changes in perception of oral dryness or salivary flow1–3,7–46; 37 had sialometry as a primary or secondary outcome; 15 studies included randomization across groups in their study design (Table 3)1,14,16,17,19,20,24,26,27,30,31,36,37,39,45; and 5 studies included a crossover design with different washout periods.8,9,15,17,22 Additional study designs that addressed xerostomia or hypofunction were pilot short-term trials, safety trials, placebo-controlled (not randomized) trials, and quasiexperimental observational designs.
A Review of the Role of Natural Products as Treatment Approaches for Xerostomia
2023, Pharmaceuticals